Related references
Note: Only part of the references are listed.Dietary Curcumin: Correlation between Bioavailability and Health Potential
Michele Dei Cas et al.
NUTRIENTS (2019)
Nanoparticle curcumin ameliorates experimental colitis via modulation of gut microbiota and induction of regulatory T cells
Masashi Ohno et al.
PLOS ONE (2017)
Short-term effects of Theracurmin dose and exercise type on pain, walking ability, and muscle function in patients with knee osteoarthritis
Yun-A Shin et al.
JOURNAL OF EXERCISE REHABILITATION (2017)
Comparison of remicade to curcumin for the treatment of Crohn's disease: A systematic review
Allaire Schneider et al.
COMPLEMENTARY THERAPIES IN MEDICINE (2017)
Protective effect of curcumin on TNBS-induced intestinal inflammation is mediated through the JAK/STAT pathway
Xingxing Zhang et al.
BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE (2016)
Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial
Alon Lang et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Colloidal Submicron-Particle Curcumin Exhibits High Absorption Efficiency -A Double-Blind, 3-Way Crossover Study-
Yoichi Sunagawa et al.
JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY (2015)
The role and utility of faecal markers in inflammatory bowel disease
Frank S. Lehmann et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2015)
Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis - A randomized, placebo-controlled, pilot study
Vikas Singla et al.
JOURNAL OF CROHNS & COLITIS (2014)
Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials
Subash C. Gupta et al.
AAPS JOURNAL (2013)
A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (TheracurminA®) in cancer patients
Masashi Kanai et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Influence of polymorphisms and TNF and IL1 beta serum concentration on the infliximab response in Crohn's disease and ulcerative colitis
Diana Lacruz-Guzman et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers
Masashi Kanai et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Curcumin and Inflammatory Bowel Disease: Biological Mechanisms and Clinical Implication
Tauseef Ali et al.
DIGESTION (2012)
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Innovative Preparation of Curcumin for Improved Oral Bioavailability
Hiroki Sasaki et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2011)
Curcumin has Bright Prospects for the Treatment of Inflammatory Bowel Disease
Hiroyuki Hanai et al.
CURRENT PHARMACEUTICAL DESIGN (2009)
Bioassay directed identification of natural aryl hydrocarbon-receptor agonists in marmalade
Karin van Ede et al.
ANALYTICA CHIMICA ACTA (2008)
The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins
Marc Veldhoen et al.
NATURE (2008)
Oral bioavailabilit of curcurnin in rat and the herbal analysis from Curcuma longa by LC-MS/MS
Kuo-Yi Yang et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Curcumin maintenance therapy for ulcerative colitis: Randomized, multicenter, double-blind, placebo-controlled trial
Hiroyuki Hanai et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice
K Sugimoto et al.
GASTROENTEROLOGY (2002)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Share Paper
